Show simple item record

dc.contributor.authorMcFall, Allison M
dc.contributor.authorDowdy, David W
dc.contributor.authorZelaya, Carla E
dc.contributor.authorMurphy, Kerry
dc.contributor.authorWilson, Tracey E
dc.contributor.authorYoung, Mary A
dc.contributor.authorGandhi, Monica
dc.contributor.authorCohen, Mardge H
dc.contributor.authorGolub, Elizabeth T
dc.contributor.authorAlthoff, Keri N
dc.date.accessioned2023-10-13T16:39:44Z
dc.date.available2023-10-13T16:39:44Z
dc.date.issued2013-11-01
dc.identifier.citationMcFall AM, Dowdy DW, Zelaya CE, Murphy K, Wilson TE, Young MA, Gandhi M, Cohen MH, Golub ET, Althoff KN; Women's Interagency HIV Study. Understanding the disparity: predictors of virologic failure in women using highly active antiretroviral therapy vary by race and/or ethnicity. J Acquir Immune Defic Syndr. 2013 Nov 1;64(3):289-98. doi: 10.1097/QAI.0b013e3182a095e9. PMID: 23797695; PMCID: PMC3816935.en_US
dc.identifier.eissn1944-7884
dc.identifier.doi10.1097/QAI.0b013e3182a095e9
dc.identifier.pmid23797695
dc.identifier.urihttp://hdl.handle.net/20.500.12648/13043
dc.description.abstractBackground: Stark racial/ethnic disparities in health outcomes exist among those living with HIV in the United States. One of 3 primary goals of the National HIV/AIDS Strategy is to reduce HIV-related disparities and health inequities.
dc.description.abstractMethods: Using data from HIV-infected women participating in the Women's Interagency HIV Study from April 2006 to March 2011, we measured virologic failure (HIV RNA >200 copies/mL) after suppression (HIV RNA < 80 copies/mL) on highly active antiretroviral therapy. We identified predictors of virologic failure using discrete time survival analysis and calculated racial/ethnic-specific population-attributable fractions (PAFs).
dc.description.abstractResults: Of 887 eligible women, 408 (46%) experienced virologic failure during the study period. Hispanic and white women had significantly lower hazards of virologic failure than African American women [Hispanic hazard ratio, (HR) = 0.8, 95% confidence interval: (0.6 to 0.9); white HR = 0.7 (0.5 to 0.9)]. The PAF of virologic failure associated with low income was higher in Hispanic [adjusted hazard ratios (aHR) = 2.2 (0.7 to 6.5), PAF = 49%] and African American women [aHR = 1.8 (1.1 to 3.2), PAF = 38%] than among white women [aHR = 1.4 (0.6 to 3.4), PAF = 16%]. Lack of health insurance compared with public health insurance was associated with virologic failure only among Hispanic [aHR = 2.0 (0.9 to 4.6), PAF = 22%] and white women [aHR = 1.9 (0.7 to 5.1), PAF = 13%]. By contrast, depressive symptoms were associated with virologic failure only among African-American women [aHR = 1.6 (1.2 to 2.2), PAF = 17%].
dc.description.abstractConclusions: In this population of treated HIV-infected women, virologic failure was common, and correlates of virologic failure varied by race/ethnicity. Strategies to reduce disparities in HIV treatment outcomes by race/ethnicity should address racial/ethnic-specific barriers including depression and low income to sustain virologic suppression.
dc.language.isoenen_US
dc.relation.urlhttps://journals.lww.com/jaids/fulltext/2013/11010/understanding_the_disparity__predictors_of.10.aspxen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleUnderstanding the disparity: predictors of virologic failure in women using highly active antiretroviral therapy vary by race and/or ethnicity.en_US
dc.typeArticle/Reviewen_US
dc.source.journaltitleJournal of acquired immune deficiency syndromes (1999)en_US
dc.source.volume64
dc.source.issue3
dc.source.beginpage289
dc.source.endpage98
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.description.versionVoRen_US
refterms.dateFOA2023-10-13T16:39:44Z
html.description.abstractBackground: Stark racial/ethnic disparities in health outcomes exist among those living with HIV in the United States. One of 3 primary goals of the National HIV/AIDS Strategy is to reduce HIV-related disparities and health inequities.
html.description.abstractMethods: Using data from HIV-infected women participating in the Women's Interagency HIV Study from April 2006 to March 2011, we measured virologic failure (HIV RNA >200 copies/mL) after suppression (HIV RNA < 80 copies/mL) on highly active antiretroviral therapy. We identified predictors of virologic failure using discrete time survival analysis and calculated racial/ethnic-specific population-attributable fractions (PAFs).
html.description.abstractResults: Of 887 eligible women, 408 (46%) experienced virologic failure during the study period. Hispanic and white women had significantly lower hazards of virologic failure than African American women [Hispanic hazard ratio, (HR) = 0.8, 95% confidence interval: (0.6 to 0.9); white HR = 0.7 (0.5 to 0.9)]. The PAF of virologic failure associated with low income was higher in Hispanic [adjusted hazard ratios (aHR) = 2.2 (0.7 to 6.5), PAF = 49%] and African American women [aHR = 1.8 (1.1 to 3.2), PAF = 38%] than among white women [aHR = 1.4 (0.6 to 3.4), PAF = 16%]. Lack of health insurance compared with public health insurance was associated with virologic failure only among Hispanic [aHR = 2.0 (0.9 to 4.6), PAF = 22%] and white women [aHR = 1.9 (0.7 to 5.1), PAF = 13%]. By contrast, depressive symptoms were associated with virologic failure only among African-American women [aHR = 1.6 (1.2 to 2.2), PAF = 17%].
html.description.abstractConclusions: In this population of treated HIV-infected women, virologic failure was common, and correlates of virologic failure varied by race/ethnicity. Strategies to reduce disparities in HIV treatment outcomes by race/ethnicity should address racial/ethnic-specific barriers including depression and low income to sustain virologic suppression.
dc.description.institutionSUNY Downstateen_US
dc.description.departmentCommunity Health Sciencesen_US
dc.description.degreelevelN/Aen_US
dc.identifier.journalJournal of acquired immune deficiency syndromes (1999)
dc.identifier.issue3en_US


Files in this item

Thumbnail
Name:
understanding_the_disparity__p ...
Size:
497.7Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International